Clinical Trials Logo

Melanoma clinical trials

View clinical trials related to Melanoma.

Filter by:

NCT ID: NCT03454035 Recruiting - Pancreatic Cancer Clinical Trials

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Start date: January 30, 2018
Phase: Phase 1
Study type: Interventional

This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4/6 inhibitor palbociclib.

NCT ID: NCT03452774 Recruiting - Breast Cancer Clinical Trials

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

NCT ID: NCT03450876 Completed - Melanoma Clinical Trials

Long Term Quality of Life in Melanoma Patients in Netherlands

Start date: December 15, 2016
Phase:
Study type: Observational

Study of late physical, psychological and social effects in patients treated with ipilimumab for advanced (stage IV or unresectable stage III) melanoma.

NCT ID: NCT03449615 Recruiting - Sentinel Lymph Node Clinical Trials

Validation of Ferromagnetic Tracer in Melanoma Sentinel Node

IMINEM
Start date: December 21, 2015
Phase: N/A
Study type: Observational

This study has been designed to validate a non-radioactive method to identify the sentinel lymph node using a superparamagnetic iron-oxide (SPIO) tracer respect to the traditional isotopic method. Both methods are used in every included patient and each patient is its own control.

NCT ID: NCT03448666 Recruiting - Malignant Melanoma Clinical Trials

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2 multicenter, open label, non-randomized, interventional study enrolling 53 patients.The objectives and purposes of the clinical study described herein are to determine if concomitant Pembrolizumab (Keytruda) and ECT treatments are safe and able to improve local and systemic response rates.ECT will be performed with the CLINIPORATOR and a single IV dose of Bleomycin

NCT ID: NCT03448497 Completed - Melanoma Clinical Trials

Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom

Start date: December 14, 2017
Phase:
Study type: Observational

The purpose of this study is to describe the first-line therapy landscape for patients with advanced melanoma and to describe clinical outcomes and healthcare resource utilization in a subset of treatment-naïve patients who initiated nivolumab + ipilimumab combination therapy.

NCT ID: NCT03445533 Terminated - Metastatic Melanoma Clinical Trials

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Start date: May 30, 2018
Phase: Phase 3
Study type: Interventional

A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma

NCT ID: NCT03438279 Completed - Melanoma Clinical Trials

Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

Start date: June 23, 2015
Phase: N/A
Study type: Observational

This study will review published trial literature and documents for Overall Survival (OS) to evaluate the association between the hazard of death and each baseline variable.

NCT ID: NCT03435640 Terminated - Colorectal Cancer Clinical Trials

REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

REVEAL
Start date: March 15, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable toxicity, death, or disease progression per RECIST 1.1. Based on Phase 1 results of the study, the decision was made not to start the Phase 2 part of the study and the study was terminated.

NCT ID: NCT03435302 Recruiting - Melanoma Clinical Trials

HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Start date: February 2014
Phase: Phase 3
Study type: Interventional

This is a a multicenter, randomized, controlled, phase III trial comparing High-Dose IFN-a2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma.The study objective is to compare efficacy and safety of High-dose IFN-a2b and temozolomide-based chemotherapy as adjuvant therapy.